Cubist Pharmaceuticals

Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.

Cubist Pharmaceuticals, INC
TypeSubsidiary (formerly: Public)
NASDAQ: CBST
IndustryPharmaceuticals (Biopharmaceuticals & Biotherapeutics)
Founded1992
Defunct2015
HeadquartersLexington, Massachusetts
Key people
Robert J. Perez, President, CEO;
ProductsProduct Pipeline
Revenue $926.4 million USD (2012)
ParentMerck & Co.
Websitewww.cubist.com

.[1] The company employed 638 people, mostly in Lexington, MA.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]

History

Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors.[4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500.[5]

In 2011, the company acquired Adolor, maker of a drug for treatment of constipation.[6]

The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.

In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion.[7]

In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015.[8]

In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.

Products

The company developed Cubicin (daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin.[9] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year). [10]

In 2011, its product pipeline focused on gram-negative bacterial infections,[11] Clostridium difficile-associated diarrhea,[12] and respiratory syncytial virus.[13]

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.[14][15]

References
  1. Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.
  2. "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.
  3. Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014
  4. "SEC Form S3 Cubist Pharmaceuticals, Inc". March 8, 2000.
  5. "100 FASTEST-GROWING COMPANIES". CNN. 2010. Retrieved 28 May 2011.
  6. Associated Press (19 Jan 2012), "Cubist Profit Down 53%", Drug Discovery & Development, Advantage Business Media, retrieved 22 Jan 2012
  7. Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
  8. Weisman, Robert (20 Oct 2014). "New Cubist Pharmaceuticals chief executive will be Robert J. Perez". www.BostonGlobe.com. Retrieved 23 Nov 2014.
  9. "Cubist Settles Teva Patent Litigation on Antibiotic Cubicin". Bloomberg. 2011-04-05. Retrieved 28 May 2011.
  10. "Optimer to Market Dificid Drug With Cubist Pharmaceuticals". Bloomberg. 2011-04-06.
  11. Donnelly, Julie M. (13 December 2011). "Cubist advances antibiotic for Gram-negative bacteria". www.bizjournals.com. Retrieved 2017-10-31.
  12. Brown, Rodney H. (6 April 2011). "Cubist - Optimer diarrhea drug could net $47M". www.bizjournals.com. Retrieved 2017-10-31.
  13. "Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs". GenomeWeb. Retrieved 2017-10-31.
  14. "Sivextro by Cubist Pharmaceuticals". www.pharmacytimes.com. Retrieved 2017-10-31.
  15. "Cubist Announces FDA Acceptance of Tedizolid New Drug Application with Priority Review | FierceBiotech". www.fiercebiotech.com. Retrieved 2017-10-31.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.